Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 15, 2024 (filed on Apr 15, 2024)Insider Name:Broadwood Partners, L.P.Ownership Type:Indirect OwnershipSecurities:Series A Convertible Preferred StockNature of Transaction:J - Other transaction# or value acquired/disposed of:--Price:--
-
Apr 15, 2024 (filed on Apr 15, 2024)Insider Name:Broadwood Partners, L.P.Ownership Type:Direct OwnershipSecurities:Series A Convertible Preferred StockNature of Transaction:J - Other transaction# or value acquired/disposed of:-2,941Price:--
-
Apr 11, 2024 (filed on Apr 15, 2024)Insider Name:Riggs JoshOwnership Type:Direct OwnershipSecurities:Common Stock, no par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:3,390Price:$2.95
-
Apr 11, 2024 (filed on Apr 15, 2024)Insider Name:Arno AndrewOwnership Type:Direct OwnershipSecurities:Common Stock, no par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:33,898Price:$2.95
-
Apr 11, 2024 (filed on Apr 15, 2024)Insider Name:Broadwood Partners, L.P.Ownership Type:Indirect OwnershipSecurities:Common Stock, no par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:--Price:--
-
Apr 11, 2024 (filed on Apr 15, 2024)Insider Name:Broadwood Partners, L.P.Ownership Type:Direct OwnershipSecurities:Common Stock, no par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:2,420,000Price:$2.92
-
Oct 10, 2023 (filed on Oct 12, 2023)Insider Name:Liu James YangOwnership Type:Direct OwnershipSecurities:Option to Purchase Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:8,482Price:--
-
Aug 15, 2023 (filed on Aug 17, 2023)Insider Name:Riggs JoshOwnership Type:Direct OwnershipSecurities:Option to Purchase Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
-
Jun 30, 2023 (filed on Jul 03, 2023)Insider Name:Gutfreund John PeterOwnership Type:Indirect OwnershipSecurities:Warrants to Purchase Common StockNature of Transaction:J - Other transaction# or value acquired/disposed of:-3,564,728Price:--
-
Jun 30, 2023 (filed on Jul 03, 2023)Insider Name:Gutfreund John PeterOwnership Type:Indirect OwnershipSecurities:Common Stock, no par valueNature of Transaction:J - Other transaction# or value acquired/disposed of:-3,085,047Price:--
Filings by filing date
-
Apr 11, 2024 (filed on Apr 15, 2024)Insider Name:Riggs JoshOwnership Type:Direct OwnershipSecurities:Common Stock, no par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:3,390Price:$2.95
-
Apr 11, 2024 (filed on Apr 15, 2024)Insider Name:Arno AndrewOwnership Type:Direct OwnershipSecurities:Common Stock, no par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:33,898Price:$2.95
-
Apr 15, 2024 (filed on Apr 15, 2024)Insider Name:Broadwood Partners, L.P.Ownership Type:Indirect OwnershipSecurities:Series A Convertible Preferred StockNature of Transaction:J - Other transaction# or value acquired/disposed of:--Price:--
-
Apr 15, 2024 (filed on Apr 15, 2024)Insider Name:Broadwood Partners, L.P.Ownership Type:Direct OwnershipSecurities:Series A Convertible Preferred StockNature of Transaction:J - Other transaction# or value acquired/disposed of:-2,941Price:--
-
Apr 11, 2024 (filed on Apr 15, 2024)Insider Name:Broadwood Partners, L.P.Ownership Type:Indirect OwnershipSecurities:Common Stock, no par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:--Price:--
-
Apr 11, 2024 (filed on Apr 15, 2024)Insider Name:Broadwood Partners, L.P.Ownership Type:Direct OwnershipSecurities:Common Stock, no par valueNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:2,420,000Price:$2.92
-
Oct 10, 2023 (filed on Oct 12, 2023)Insider Name:Liu James YangOwnership Type:Direct OwnershipSecurities:Option to Purchase Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:8,482Price:--
-
Aug 15, 2023 (filed on Aug 17, 2023)Insider Name:Riggs JoshOwnership Type:Direct OwnershipSecurities:Option to Purchase Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
-
Jun 30, 2023 (filed on Jul 03, 2023)Insider Name:Gutfreund John PeterOwnership Type:Indirect OwnershipSecurities:Warrants to Purchase Common StockNature of Transaction:J - Other transaction# or value acquired/disposed of:-3,564,728Price:--
-
Jun 30, 2023 (filed on Jul 03, 2023)Insider Name:Gutfreund John PeterOwnership Type:Indirect OwnershipSecurities:Common Stock, no par valueNature of Transaction:J - Other transaction# or value acquired/disposed of:-3,085,047Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 15 CUSHING IRVINE CA 92618 |
Tel: | N/A |
Website: | https://oncocyte.com |
IR: | See website |
Key People | ||
Joshua Riggs President, Chief Executive Officer, Director | James Liu Interim Principal Financial Officer, Principal Accounting Officer, Senior Director, Controller |
Business Overview |
Oncocyte Corporation is a precision diagnostics company. The Company is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company's products include DetermaIO, VitaGraft, and DetermaCNI. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor, combined with information from the wound response surrounding the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test. |
Financial Overview |
For the fiscal year ended 31 December 2023, OncoCyte Corp revenues increased 57% to $1.5M. Net loss applicable to common stockholders excluding extraordinary items increased 35% to $25.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Fair Value Adjustments on Other Assets decrease of 81% to $5.8M (income). |
Employees: | 75 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $1.50M as of Dec 31, 2023 |
EBITDA (TTM): | -$15.07M as of Dec 31, 2023 |
Net annual income (TTM): | -$25.80M as of Dec 31, 2023 |
Free cash flow (TTM): | N/A |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 8,273,073 as of Apr 3, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |